727 FinancePANews October 21 news, according to an official OpenAI announcement, OpenAI has acquired Orchestra Bio, a drug R&D collaboration platform. The platform helps biopharmaceutical teams coordinate complex drug development processes, allowing scientists and project leads to delegate the monitoring and tracking of research and trials to AI agents. OpenAI stated that it will integrate Orchestra's team and technology with Rosalind, its life sciences research AI model and tool, to help new therapies reach patients faster.
OpenAI acquires drug R&D collaboration platform Orchestra Bio
Notícias relacionadas
Financiamento Semanal | Kalshi conclui rodada Série G de US$ 1 bilhão, liderada pela Sequoia Capital e Wellington Management.
A Kalshi concluiu uma rodada de financiamento Série G de US$ 1 bilhão, alcançando uma avaliação pós-money de US$ 40 bilhões, quase o dobro da avaliação de US$ 2...